WALTHAM, Mass., May 21, 2019 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,293,159 titled “Measuring the ‘on-skin’ time of a Transcutaneous Electrical Nerve Stimulator (TENS) device in order to minimize skin irritation due to excessive uninterrupted wearing of the same.” The patent covers novel methods to help Quell® users safely obtain wearable TENS therapy over extended time periods. The patent includes claims for methods to monitor the amount of time that the Quell device is worn by a user and to provide the user with personalized notifications.
"We are pleased to have received this latest patent for Quell technology," said Shai N. Gozani, M.D., Ph.D., President and CEO of NeuroMetrix. "Quell is unique in the fact that the technology is designed for up to 24/7 use and therefore safe management of the skin-device interface is important. This patent covers methods that address and personalize this requirement."
About Quell
Quell is an advanced, wearable pain-relief technology. It can be worn during the day while active and at night while sleeping. Quell is drug-free and has been cleared by the FDA for relief and management of chronic pain without a prescription. Quell users can personalize and manage therapy discreetly via the Quell app. Quell also offers health tracking relevant to chronic pain sufferers including pain, sleep, activity, and gait. Quell users can synchronize their data with the Quell Health Cloud™, which provides customized feedback and powers one of the largest chronic pain databases. Quell is available online and through select retailers. Visit QuellRelief.com for more information.
About NeuroMetrix
NeuroMetrix is an innovation driven healthcare company combining neurostimulation and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The company's markets Quell, an over-the-counter wearable therapeutic device for chronic pain. The company also markets DPNCheck®, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. For more information, please visit NeuroMetrix.com.
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
neurometrix.ir@neurometrix.com
Source: NeuroMetrix, Inc.